BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 14, 2018
View Archived Issues
Novartis studies LHC-165 alone and with PDR-001 in advanced malignancies
Read More
vTv reports Part B results from STEADFAST study of azeliragon in mild Alzheimer's disease
Read More
Discovery and characterization of BWC-0977, a dual bacterial topoisomerase inhibitor
Read More
Application for Furoscix receives complete response letter from the FDA
Read More
Seattle Genetics doses first patient in phase II study of tisotumab vedotin for cervical cancer
Read More
Researchers present phase I data for neoadjuvant anti-OX40 therapy with MEDI-6469 in HNSCC
Read More
First patient dosed in phase I study of MET-409
Read More
Vistusertib administration feasible prior to radical prostatectomy
Read More
Flex Pharma stops two phase II clinical studies of FLX-787
Read More
First-in-human data demonstrate early signs of antitumor activity for BI-836880
Read More
FDA approves moxidectin to treat river blindness
Read More
CFDA grants priority review to Pharnext's PXT-3003 for CMT1A
Read More
Improved pharmacokinetic properties of trans-translation inhibitors efficacious against gonorrhea
Read More
Sage and Shionogi enter strategic collaboration for SAGE-217 in Japan, Taiwan and South Korea
Read More
BridgeBio Pharma launches CoA Therapeutics
Read More
FDA approves Keytruda for refractory or relapsed primary mediastinal large B-cell lymphoma
Read More
Prana opens enrollment in phase I study of PBT-434
Read More
Sun BioPharma announces dosing of first patients in second clinical study of SBP-101
Read More
Subcutaneous efgartigimod has comparable characteristics to intravenous formulation in phase I study
Read More
Long-term articular cartilage structure modification seen with sprifermin in knee osteoarthritis
Read More
Verseon prepares for phase I study of oral anticoagulant VE-1902
Read More
Allos initiates phase I RSV challenge study with JNJ-64417184
Read More
Phase II results presented from KEYNOTE-158 study of pembrolizumab in SCLC
Read More
